19 June 2013
Keywords: positive, new, data, aeterna, impavido, canada, released
Article | 11 August 2003
Canada's AEterna has released encouraging results from a Phase III trial examining the potential of its Impavido (miltefosine) for the ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscriptions are £60 per month, pay as you go.
Find out more details.
11 August 2003
© 2013 thepharmaletter.com